Mast cells and histamine enhance the proliferation of non-small cell lung cancer cells

Lung Cancer

Volumn 75, Issue 1, 2012, Pages 38-44

  Stoyanov, Evgeniy ^a   Uddin, Mohib ^b   Mankuta, David ^c   Dubinett, Steven M ^d   Levi Schaffer, Francesca ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Histamine; LLC; Mast cells; Nedocromil sodium; Non small cell lung cancer (NSCLC); Sash mice

Indexed keywords

1 (5 CHLORO 2 INDOLYLCARBONYL) 4 METHYLPIPERAZINE; CIMETIDINE; HISTAMINE; HISTAMINE H1 RECEPTOR; HISTAMINE H2 RECEPTOR; HISTAMINE H4 RECEPTOR; MEPYRAMINE; MITOGEN ACTIVATED PROTEIN KINASE; NEDOCROMIL SODIUM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL FUNCTION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MAST CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH;

ADENOCARCINOMA; ADENOCARCINOMA, BRONCHIOLO-ALVEOLAR; ANIMALS; CARCINOMA, LEWIS LUNG; CARCINOMA, NON-SMALL-CELL LUNG; CELL DIFFERENTIATION; CELL GROWTH PROCESSES; CELL LINE, TUMOR; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HISTAMINE; HUMANS; LUNG NEOPLASMS; MAST CELLS; MICE; MICE, INBRED C57BL; NEOPLASM METASTASIS; PHOSPHORYLATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 83555173454     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.05.029     Document Type: Article

References (44)

1. Jemal A., Tiwari R.C., Murray T., Ghafoor A., Samuels A., Ward E., et al. Cancer statistics 2004. CA Cancer J Clin 2004, 54:8-29.
2. Ribatti D., Crivellato E., Roccaro A.M., Ria R., Vacca A. Mast cell contribution to angiogenesis related to tumor progression. Clin Exp Allergy 2004, 34:1660-1664.
3. Dubinett S.M., Sharma S., Huang M., Dohadwala M., Pold M., Mao J.T. COX2 in lung cancer. Prog Exp Tumor Res 2003, 37:138-162.
4. De Visser K.E., Coussens L.M. The inflammatory tumor microenviroment and its impact on cancer development Infection and inflammation: impacts on oncogenesis. Contrib Microbiol 2006, 13:118-137.
5. Mueller M.M., Fusenig N.E. Friends or foes - bipolar effects of the tumor stroma in cancer. Nat Rev Cancer 2004, 4:839-849.
6. He Q., Luo X., Huang Y., Sheikh M.S. Apo2L/TRAIL differentially modulates the apoptotic effects of sulindac and a COX2 selective non-steroidal anti-inflammatory agent in Bax-deficient cells. Oncogene 2002, 21:6032-6040.
7. Galli S.J., Tsai M. Mast cells in allergy and infection: versatile effector and regulatory cells in innate and adaptive immunity. Eur J Immunol 2010, 40(7):1843-1851.
8. Sinnamon M.J., Carter K.J., Sims L.P., Lafleur B., Fingleton B., Matrisian L.M. A protective role of mast cells in intestinal tumorigenesis. Carcinogenesis 2008, 29:880-886.
9. Boldrini L., Gisfredi S., Ursino S., Lucchi M., Melfi F., Mussi A., et al. Tumor necrosis factor-alpha: prognostic role and relationship with interleukin-8 and endothelin-1 in non-small cell lung cancer. Int J Mol Med 2006, 17:887-892.
10. Samoszuk M., Kanakubo E., Chan J.K. Degranulating mast cells in fibrotic regions of human tumors and evidence that mast cell heparin interferes with the growth of tumor cells through a mechanism involving fibroblasts. BMC Cancer 2005, 5:121.
11. Theoharides T.C., Conti P. Mast cells: the Jekyll and Hyde of tumor growth. Trends Immunol 2004, 25:235-241.
12. Ch'ng S., Wallis R.A., Yuan L., Davis P.F., Tan S.T. Mast cells and cutaneous malignancies. Mod Pathol 2006, 19:149-159.
13. Imada D., Shijubo N., Kojima H., Abe S. Mast cells correlate with angiogenesis and poor outcome in stage I lung adenocarcinoma. Eur Respir J 2000, 15:1087-1093.
14. 4 receptor antagonist with anti-inflammatory properties. J Pharmacol Exp Ther 2004, 309:404-413.
15. Haak-Frendscho M., Darvas Z., Hegyesi H. Histidine decarboxylase expression in human melanoma. J Invest Dermatol 2000, 115:345-352.
16. Hegyesi H., Somlai B., Varga V.L. Suppression of melanoma cell proliferation by histidine decarboxylase specific antisense oligonucleotides. J Invest Dermatol 2001, 117:151-153.
17. Graff L., Frungieri M., Zanner R., Pohlinger A., Prinz C., Gratzl M. Expression of histidine decarboxylase and synthesis of histamine by human SCLC. Am J Pathol 2002, 160:1561-1565.
18. Garcia-Caballero M., Neugebauer E., Campos R., Nunez de Castro I., Vara-Thorbeck C. Increased histidine decarboxylase (HDC) activity in human colorectal cancer: results of a study on ten patients. Agents Actions 1988, 23:357-360.
19. Lampiasi N., Azzolina A., Montalto G., Cervello M. Histamine and spontaneously released mast cells granules affect the cell growth of human hepatocellular carcinoma cells. Exp Mol Med 2007, 39:284-294.
20. Dohadwala M., Batra R.K., Luo J., Lin Y., Krysan K., Pold M., Sharma S., et al. Autocrine/paracrine PGE2 production by NSCLS cells regulates MMP-2 and CD44 in COX2-dependent invasion. J Biol Chem 2002, 277:50828-50833.
21. Dohadwala M., Luo J., Zhu L., Lin Y., Dougherty G.J., Sharma S., Huang M., et al. NSCLC COX2-dependent invasion is mediated by CD44. J Biol Chem 2001, 276:20809-20812.
22. Bachelet I., Munitz A., Mankutad D., Levi-Schaffer F. Mast cells costimulation by CD226/CD112 (DNAM-1/Nectin-2). A novel interface in the allergic process. J Bio Chem 2006, 281:27190-27196.
23. Levi-Schaffer F., Shalit M. Proliferation and functional responses of bone marrow-derived mast cells after activation. Cell Immunol 1993, 148:435-443.
24. Lavens S.E., Proud D., Warnr J.A. A sensitive colorimetric assay for the release of tryptase from human lung mast cells in vitro. J Immunol methods 1993, 166(1):93-102.
25. Zudaire E., Martinez A., Garayoa M., Pio R., Kaur G., Woolhiser M.R., et al. Adrenomedullin is a cross-talk molecule that regulates tumor and mast cell function during human carcinogenesis. Am J Pathol 2006, 168:280-291.
26. Papa S., Zamai L., Cecchini T., Del Grande P., Vitale M. Cell cycle analysis in flow cytometry: use of BrdU labelling and side scatter for the detection of the different cell cycle phases. Cytotechnology 1991, 5:103-106.
27. Nagle D.L., Kozak C.A., Mano H., Chapman V.M., Bucan M. Physical mapping of the Tec and Gabrbi loci reveals that the Wsh mutation on mouse chromosome 5 is associated with an inversion. Hum Mol Genet 1995, 11:2073-2079.
28. Levi-Schaffer F., Goldenhersh M.A., Segal1 V., Nagler A. Nedocromil sodium ameliorates skin manifestations in a murine model of chronic graft-versus-host disease. Bone Marrow Transplant 1997, 19:823-828.
29. Pfander D., Kortje D., Zimmermann R., Weseloh G., Kirsch T., Gesslein M., et al. VEGF in articular cartilage of healthy and osteoarthritic human knee joints. Ann Rheum Dis 2001, 60:1070-1073.
30. 4 receptors suggests disturbance of local regulation in human colorectal tumors by histamine. Eur J Cell Biol 2008, 87:227-236.
31. Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002, 420:860-867.
32. Han Z.B., Ren H., Zhao H., Chi Y., Liu Y., Zhang L., et al. Hypoxia-inducible factor (HIF)-1? directly enhances the transcriptional activity of SCF in response to hypoxia and EGF. Carcinogenesis 2008, 29:1853-1861.
33. Gauliard B., Grieve D., Wilson R., Crozier A., Jenkins C., Mullen W.D., et al. The effects of dietary phenolic compounds on cytokine and antioxidant production by A549 cells. J Med Food 2008, 11:382-384.
34. Kim S.J., Jeong H.J., Moon P.D., Myung N.Y., Kim M.C., Kang T.H., et al. The COX2 inhibitor SC-236 exerts anti-inflammatory effects by suppressing phosphorylation of ERK in a murine model. Life Sci 2007, 81:863-872.
35. 1 receptor. Inflamm Res 2006, 55:393-398.
36. Adams W.J., Lawson J.A., Morris D.L. Cimetidine inhibits in vivo growth of human colon cancer and reverses histamine stimulated in vitro and in vivo growth. Gut 1994, 35:1632-1636.
37. 2 antagonists on proliferation and apoptosis in human colorectal cancer cell lines. Dig Dis Sci 2004, 49:1634-1640.
38. Lazar-Molnar E., Hegyesi H., Pallinger E., Kovacs P., Tath S., Fitzsimons C., et al. Inhibition of human primary melanoma cell proliferation by histamine is enhanced by IL-6. Eur J Clin Invest 2002, 32:743-749.
39. Brognard J., Dennis P.A. Variable apoptotic response of NSCLC cells to inhibition of the MEK/ERK pathway by small molecules or dominant negative mutants. Cell Death Differ 2002, 9:893-904.
40. Sebolt-Leopold J.S., Dudley D.T., Herrera R., Van Becelaere K., Wiland A., Gowan R.C., et al. Blockade of the MAPK pathway suppresses growth of colon tumors in vivo. Nat Med 1999, 5:810-816.
41. Wedemeyer J., Galli S.J. Decreased susceptibility of mast-cell Kit(W)/Kit(W-v) mice to the development of 1,2-dimethylhydrazine-induced intestinal tumors. Lab Invest 2005, 85:388-396.
42. Benitez-Bribiesca L., Wong A., Utrera D., Castellanos E. The role of mast cell tryptase in nreoangiogenesis of premalignant and malignant lesions of the uterine cervix. J Histochem Cytochem 2001, 49:1061-1062.
43. Starkey J.R., Taubenberger S. Mast cell-deficient W/Wv mice exhibit a decreased rate of tumor angiogenesis. Int J Cancer 1988, 42:48-52.
44. Cianchi F., Schiavone N. The role of COX2 in mediating the effects of histamine on cell proliferation and VEGF production in colorectal cancer. Clin Cancer Res 2005, 11:6807-6815.